Inactivated rabies viruses carrying canine distemper glycoproteins protect against both pathogens
Currently licensed live attenuated canine distemper vaccines are highly effective. However, they retain the potential to cause disease in very susceptible species. Researchers at Paul-Ehrlich-Institut and Thomas Jefferson University have generated an inactivated candidate vaccine that induces protective immunity against both rabies and canine distemper and has an excellent safety profile.
EU project for the development of Crimean-Congo Haemorrhagic Fever virus (CCHFV) vaccines starts
On 25 and 26 January the CCHFVaccine kick-off meeting took place at the Paul-Ehrlich-Institut. CCHFVaccine is a multinational and interdisciplinary research project. This consortium will investigate model vaccines against Crimean-Congo haemorrhagic fever for the protection of humans and animals. The Paul-Ehrlich-Institut and the Friedrich-Loeffler-Institut are among the 14 partners.
Call for comments – European Paediatric Regulation
The European Paediatric Regulation has now been in force for nearly ten years. The European Commission has requested stakeholders to submit their comments on the consultation paper provided by the European Medicines Agency (EMA) by 20 February 2016. The Paul-Ehrlich-Institut expressly supports this request in the interest of paediatric health.